NASDAQ:ICAD - iCAD Stock Price, Price Target & More

$3.50 +0.11 (+3.24 %)

(As of 04/23/2018 04:00 PM ET)

Previous Close$3.39

Today's Range$3.38 - $3.51

52-Week Range$2.93 - $6.07

Volume17,306 shs

Average Volume34,149 shs

Market Capitalization$56.29 million

P/E Ratio-5.62

Dividend YieldN/A

Beta1.44

About iCAD (NASDAQ:ICAD)

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorComputer and Technology

SymbolNASDAQ:ICAD

CUSIPN/A

Webwww.icadmed.com

Phone603-882-5200

Debt

Debt-to-Equity Ratio0.36%

Current Ratio1.76%

Quick Ratio1.58%

Price-To-Earnings

Trailing P/E Ratio-5.62

Forward P/E Ratio-8.97

P/E GrowthN/A

Sales & Book Value

Annual Sales$28.10 million

Price / Sales2.07

Cash FlowN/A

Price / CashN/A

Book Value$0.86 per share

Price / Book4.07

Profitability

EPS (Most Recent Fiscal Year)($0.61)

Net Income$-14,250,000.00

Net Margins-50.73%

Return on Equity-48.67%

Return on Assets-28.20%

Miscellaneous

Employees119

Outstanding Shares16,600,000

How to Become a New Pot Stock Millionaire

iCAD (NASDAQ:ICAD) Frequently Asked Questions

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

How were iCAD's earnings last quarter?

iCAD Inc. (NASDAQ:ICAD) posted its quarterly earnings results on Thursday, March, 22nd. The technology company reported ($0.14) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.14). The technology company had revenue of $7.90 million for the quarter, compared to analyst estimates of $7.43 million. iCAD had a negative net margin of 50.73% and a negative return on equity of 48.67%. View iCAD's Earnings History.

When is iCAD's next earnings date?

iCAD is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for iCAD.

What price target have analysts set for ICAD?

1 analysts have issued 12-month target prices for iCAD's stock. Their predictions range from $11.00 to $11.00. On average, they expect iCAD's stock price to reach $11.00 in the next year. View Analyst Ratings for iCAD.

Who are some of iCAD's key competitors?

Some companies that are related to iCAD include Nuvectra (NVTR), SeaSpine (SPNE), IRadimed (IRMD), Restoration Robotics (HAIR), Apollo Endosurgery (APEN), Alphatec (ATEC), INVO Bioscience (IVOB), Invuity (IVTY), Sensus Healthcare (SRTS), Motus GI (MOTS), SANUWAVE (SNWV), Obalon Therapeutics (OBLN), Neovasc (NVCN), Spectral Medical (EDTXF) and Repro-Med Systems (REPR).

Who are iCAD's key executives?

iCAD's management team includes the folowing people:

Mr. Kenneth M. Ferry, CEO & Director (Age 64)
Mr. Richard C. Christopher, Exec. VP, CFO, Treasurer & Sec. (Age 48)
Ms. Stacey M. Stevens, Exec. VP and Chief Strategy & Commercial Officer (Age 50)
Mr. R. Scott Areglado, VP & Corp. Controller
Ms. Annette L. Heroux, VP of Admin. (Age 61)

Has iCAD been receiving favorable news coverage?

News articles about ICAD stock have trended somewhat positive on Monday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. iCAD earned a media sentiment score of 0.12 on Accern's scale. They also gave news headlines about the technology company an impact score of 45.99 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $3.50.

How big of a company is iCAD?

iCAD has a market capitalization of $56.29 million and generates $28.10 million in revenue each year. The technology company earns $-14,250,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. iCAD employs 119 workers across the globe.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]

MarketBeat Community Rating for iCAD (ICAD)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		57 (Vote Outperform)
Underperform Votes:		64 (Vote Underperform)
Total Votes:		121

MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days.

iCAD (NASDAQ:ICAD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for iCAD in the last 12 months. Their average twelve-month price target is $11.00, suggesting that the stock has a possible upside of 214.29%. The high price target for ICAD is $11.00 and the low price target for ICAD is $11.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$11.00	$11.00	$11.00	$11.00
Price Target Upside:	214.29% upside	179.19% upside	179.19% upside	179.19% upside

iCAD (NASDAQ:ICAD) Consensus Price Target History

Price Target History for iCAD (NASDAQ:ICAD)

iCAD (NASDAQ:ICAD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
7/25/2017	Laidlaw	Reiterated Rating	Buy	$11.00	Medium

(Data available from 4/23/2016 forward)

iCAD (NASDAQ:ICAD) Earnings History and Estimates Chart

Earnings by Quarter for iCAD (NASDAQ:ICAD)

iCAD (NASDAQ:ICAD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.39)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.14)	($0.14)	($0.14)
Q2 2018	1	($0.10)	($0.10)	($0.10)
Q3 2018	1	($0.09)	($0.09)	($0.09)
Q4 2018	1	($0.06)	($0.06)	($0.06)

iCAD (NASDAQ ICAD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/1/2018
3/22/2018	Q4 2017	($0.14)	($0.14)	$7.43 million	$7.90 million	View	Listen
11/8/2017	Q3 2017	($0.14)	($0.13)	$7.43 million	$7.00 million	View	N/A
8/8/2017	Q2 2017	($0.19)	($0.1610)	$6.41 million	$6.41 million	View	Listen
5/4/2017	Q1 2017	($0.20)	($0.18)	$6.40 million	$6.79 million	View	Listen
3/8/2017	Q4 2016	($0.17)	($0.20)	$6.60 million	$6.93 million	View	Listen
11/2/2016	Q3 2016	($0.14)	($0.16)	$7.44 million	$6.00 million	View	N/A
7/27/2016	Q2	($0.14)	($0.09)	$6.99 million	$7.37 million	View	Listen
5/3/2016	Q1	($0.14)	($0.17)	$7.27 million	$6.04 million	View	N/A
3/1/2016	Q4	($0.17)	($0.14)	$7.77 million	$7.61 million	View	N/A
10/29/2015	Q315	($0.07)	($0.03)	$8.09 million	$9.58 million	View	Listen
4/30/2015	Q1 2015	($0.01)	$0.02	$12.96 million	$13.22 million	View	N/A
2/24/2015	Q414	$0.04	$0.01	$13.30 million	$13.20 million	View	N/A
10/28/2014	Q3 2014		$0.04	$11.56 million	$12.57 million	View	N/A
7/30/2014	Q2 2014	($0.02)	($0.04)	$9.02 million	$9.67 million	View	N/A
5/6/2014	Q1	($0.15)	($0.12)	$7.95 million	$8.50 million	View	Listen
2/19/2014	Q4	($0.17)	($0.41)	$8.25 million	$9.14 million	View	Listen
10/29/2013	Q313	($0.20)	($0.11)	$8.07 million	$8.30 million	View	Listen
7/29/2013	Q2 2013	($0.25)	($0.12)	$7.56 million	$7.71 million	View	Listen
4/29/2013	Q1 2013	($0.14)	($0.11)	$7.20 million	$7.93 million	View	N/A
2/19/2013	Q4 2012		($0.15)	$6.61 million	$7.82 million	View	Listen
10/30/2012	Q3 2012	($0.20)	($0.15)			View	N/A
8/1/2012	Q2 2012	($0.25)	($0.26)			View	N/A
5/7/2012	Q1 2012	($0.30)	($0.26)			View	N/A
2/27/2012	Q4 2011	($0.25)	($0.21)			View	N/A
10/26/2011	Q3 2011	($0.35)	($0.14)			View	N/A
7/27/2011	Q2 2011	($0.35)	($0.35)			View	N/A
5/3/2011	Q1 2011	($0.30)	($0.32)			View	N/A
3/23/2011	Q4 2010	($0.10)	($0.07)			View	N/A
11/3/2010	Q3 2010	($0.05)	($0.15)			View	N/A
7/28/2010	Q2 2010		($0.08)			View	N/A
4/28/2010	Q1 2010	($0.05)	($0.15)			View	N/A
2/22/2010	Q4 2009	$0.05	$0.05			View	N/A
10/28/2009	Q3 2009	($0.05)	$0.01			View	N/A
7/29/2009	Q2 2009	($0.05)	($0.16)			View	N/A
4/29/2009	Q1 2009	($0.15)	($0.11)			View	N/A
2/25/2009	Q4 2008	$0.05	$0.04			View	N/A
10/29/2008	Q3 2008	$0.15	$0.23			View	N/A
7/31/2008	Q2 2008	$0.15	$0.27			View	N/A
5/7/2008	Q1 2008	($0.05)	($0.06)			View	N/A
3/6/2008	Q4 2007		$0.06			View	N/A

(Earnings results data provided by Zacks Investment Research)

iCAD (NASDAQ:ICAD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

iCAD (NASDAQ ICAD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.20%
Institutional Ownership Percentage: 20.98%

Insider Trading History for iCAD (NASDAQ:ICAD)

Institutional Ownership by Quarter for iCAD (NASDAQ:ICAD)

iCAD (NASDAQ ICAD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/23/2017	Dr Lawrence Howard	Director	Buy	10,000	$3.33	$33,300.00	488,022
11/14/2016	Kenneth M Ferry	CEO	Buy	10,000	$3.50	$35,000.00	334,136
3/4/2016	Kenneth M Ferry	CEO	Buy	25,000	$4.45	$111,250.00	249,136
3/4/2016	Kevin C Burns	CFO	Buy	10,000	$4.44	$44,400.00	183,734
3/19/2015	Kenneth M Ferry	CEO	Sell	100,000	$10.00	$1,000,000.00
3/12/2015	Somu Subramaniam	Director	Sell	50,762	$9.23	$468,533.26
2/10/2015	Stacey M Stevens	SVP	Sell	27,298	$10.00	$272,980.00
12/3/2014	Stacey M Stevens	SVP	Sell	2,502	$10.00	$25,020.00
12/2/2014	Stacey M Stevens	SVP	Sell	503	$10.01	$5,035.03
12/1/2014	Stacey M Stevens	SVP	Sell	299	$10.00	$2,990.00
11/11/2014	Kenneth M Ferry	CEO	Sell	18,318	$11.09	$203,146.62
11/3/2014	Stacey M Stevens	VP	Sell	10,000	$11.31	$113,100.00
10/1/2014	Stacey M Stevens	VP	Sell	13,333	$10.00	$133,330.00
9/3/2014	Stacey M Stevens	VP	Sell	10,000	$10.94	$109,400.00
8/27/2014	Kevin C Burns	CFO	Sell	36,439	$10.44	$380,423.16
8/25/2014	Kenneth M Ferry	CEO	Sell	40,000	$10.71	$428,400.00
8/20/2014	Stacey M Stevens	VP	Sell	5,000	$10.57	$52,850.00
8/19/2014	Kenneth M Ferry	CEO	Sell	20,000	$10.06	$201,200.00
8/26/2013	Kenneth M Ferry	CEO	Buy	5,000	$5.55	$27,750.00
5/3/2013	Kevin C Burns	CFO	Buy	2,900	$5.19	$15,051.00
8/24/2012	Kevin C Burns	CFO	Buy	15,000	$2.08	$31,200.00
8/17/2012	Kevin C Burns	CFO	Buy	28,939	$2.90	$83,923.10

(Data available from 1/1/2013 forward)

iCAD (NASDAQ ICAD) News Headlines

Source:

Date	Headline
	Java Blues by ICAD to Make Global Debut at The Superdesign Show Milan finance.yahoo.com - April 23 at 8:11 AM
	iCAD Announces Presentation of Positive Clinical Data on Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers at ESTRO 37 finance.yahoo.com - April 19 at 8:11 AM
	Laidlaw Reaffirms Buy Rating for iCAD (ICAD) www.americanbankingnews.com - April 16 at 12:37 PM
	Active-Investors: Free Post Earnings Research Report: Nutanix's Revenues Surged 44%; Net Loss Narrowed www.finanznachrichten.de - April 12 at 8:25 AM
	iCAD (ICAD) Upgraded to Sell by ValuEngine www.americanbankingnews.com - April 8 at 12:22 PM
	Zacks Investment Research Weighs in on iCAD Inc.'s Q1 2018 Earnings (ICAD) www.americanbankingnews.com - April 5 at 7:38 AM
	iCAD Inc. (ICAD) to Post FY2020 Earnings of $0.04 Per Share, Zacks Investment Research Forecasts www.americanbankingnews.com - April 4 at 8:10 AM
	BRIEF-Icad Q4 Gaap Loss Per Share $0.26 www.reuters.com - March 24 at 5:19 PM
	iCAD reports stronger Q4 results seekingalpha.com - March 23 at 5:48 PM
	iCAD (ICAD) Releases Quarterly Earnings Results, Meets Estimates www.americanbankingnews.com - March 23 at 8:14 AM
	Edited Transcript of ICAD earnings conference call or presentation 22-Mar-18 8:30pm GMT finance.yahoo.com - March 23 at 8:14 AM
	iCAD Reports Fourth Quarter and Full-Year 2017 Financial Results finance.yahoo.com - March 22 at 5:41 PM
	iCAD (ICAD) Set to Announce Quarterly Earnings on Thursday www.americanbankingnews.com - March 19 at 8:38 AM
	iCAD to Report Fourth Quarter and Fiscal 2017 Financial Results on Thursday, March 22, 2018 finance.yahoo.com - March 16 at 8:13 AM
	iCAD (ICAD) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - March 13 at 10:19 PM
	Form 4 ICAD INC For: Feb 14 Filed by: Ecock Anthony F www.streetinsider.com - February 16 at 5:21 PM
	iCAD Named a Top Artificial Intelligence Medical Imaging Solution Provider by Healthcare Tech Outlook finance.yahoo.com - February 8 at 3:39 PM
	BRIEF-iCAD Expects To Reduce About 18 Pct Of Workforce Across Skin Subscription Business www.reuters.com - January 5 at 3:46 PM
	iCAD (ICAD) Upgraded at ValuEngine www.americanbankingnews.com - January 4 at 10:32 PM
	iCAD (ICAD) Rating Lowered to Strong Sell at ValuEngine www.americanbankingnews.com - December 20 at 10:10 PM
	ICAD: Study Shows IORT Superior To EBRT in Quality of Life, Cost finance.yahoo.com - December 15 at 11:47 AM
	Two Centers from The US Oncology Network Adopt iCAD’s Xoft Electronic Brachytherapy System for Treatment of Early-Stage Non-Melanoma Skin Cancer finance.yahoo.com - December 12 at 11:56 AM
	iCAD Announces Study Demonstrating Economic and Health Benefits of Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer Treatment finance.yahoo.com - December 7 at 11:47 AM
	iCAD’s PowerLook® Tomo Detection Experiences Growing Adoption finance.yahoo.com - November 27 at 5:25 PM
	Are iCAD Inc’s (ICAD) Interest Costs Too High? finance.yahoo.com - November 22 at 12:54 AM
	ICAD: Q3 Detection and Therapy Results Solid. Tomo Growth To Accelerate finance.yahoo.com - November 13 at 7:45 PM
	Edited Transcript of ICAD earnings conference call or presentation 8-Nov-17 9:30pm GMT finance.yahoo.com - November 11 at 10:46 AM
	iCAD Announces Positive Clinical Data on Xoft System for Non-Melanoma Skin Cancer Treatment Selected as “Best of ASTRO 2017” finance.yahoo.com - November 11 at 10:46 AM
	icad inc. (ICAD) Issues Earnings Results www.americanbankingnews.com - November 9 at 7:48 PM
	Icad reports 3Q loss www.cnbc.com - November 9 at 2:35 AM
	Imaging For Women Now Offering ICAD's PowerLook® Tomo Detection For Digital Breast Tomosynthesis www.thestreet.com - November 8 at 4:32 PM
	iCAD, Inc. to Host Earnings Call finance.yahoo.com - November 8 at 4:32 PM
	iCAD Reports Third Quarter 2017 Financial Results finance.yahoo.com - November 8 at 4:32 PM
	Imaging for Women Now Offering iCAD’s PowerLook® Tomo Detection for Digital Breast Tomosynthesis finance.yahoo.com - November 8 at 10:05 AM
	The global brachytherapy market is expected to reach USD 486.9 million by 2025 finance.yahoo.com - November 3 at 8:26 AM
	icad inc. (ICAD) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - November 2 at 9:53 AM
	iCAD to Report Third Quarter 2017 Financial Results on Wednesday, November 8 finance.yahoo.com - November 2 at 1:57 AM
	iCAD’s PowerLook Tomo Detection for Digital Breast Tomosynthesis Named 2017 Product of the Year by New Hampshire High Technology Council finance.yahoo.com - October 26 at 12:40 PM
	iCAD Announces Presentation of New Clinical Data on Xoft System for Treatment of Nonmelanoma Skin Cancer and Early-Stage Breast Cancer at ASTRO 2017 finance.yahoo.com - September 25 at 9:54 AM
	iCAD to Present at the Cantor Fitzgerald Global Healthcare Conference finance.yahoo.com - September 20 at 4:05 PM
	Tech PR Agency ARPR Adds Two Marquee Health IT Brands to Its Portfolio; Erin Bocherer Hired as First Practice Group Director www.marketwatch.com - September 14 at 11:31 PM
	ETFs with exposure to iCAD, Inc. : September 6, 2017 finance.yahoo.com - September 6 at 6:15 AM
	iCAD, Inc. :ICAD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 31, 2017 finance.yahoo.com - August 31 at 7:43 PM
	BRIEF-ICAD Inc ‍announces approval of Xoft Axxent balloon applicators by China FDA www.reuters.com - August 31 at 6:00 AM
	iCAD Announces Approval of Xoft® Axxent® Balloon Applicators by China Food & Drug Administration for Treatment of Early-Stage Breast Cancer finance.yahoo.com - August 31 at 6:00 AM
	icad inc. (ICAD) Director Acquires $33,300.00 in Stock www.americanbankingnews.com - August 24 at 4:30 PM
	icad inc. (ICAD) Expected to Earn FY2019 Earnings of $0.03 Per Share www.americanbankingnews.com - August 18 at 2:08 PM
	ICAD: A Look Behind Q2 Numbers. U.S. Tomo Launch Encouraging finance.yahoo.com - August 18 at 5:09 AM
	Edited Transcript of ICAD earnings conference call or presentation 8-Aug-17 8:30pm GMT finance.yahoo.com - August 9 at 5:29 AM
	icad inc. (NASDAQ:ICAD) Issues Quarterly Earnings Results www.americanbankingnews.com - August 8 at 9:30 PM

iCAD (NASDAQ:ICAD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

iCAD (NASDAQ:ICAD) Income Statement, Balance Sheet and Cash Flow Statement

iCAD (NASDAQ ICAD) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff